TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38678451
Drug: 38% SDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% SDF gel and 2.5% sodium fluoride varnish
Study: 38678757
Drug: iNAP® Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNAP® Sleep Therapy System
Study: 38679035
Drug: Vaccinee group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinee group (tetravalent dengue purified inactivated vaccine prime followed by live-attenuated vaccine boost)
Study: 38679140
Drug: Telephone-delivered motivational
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered motivational interviewing (MI) engagement session and 8 sessions of MI-Cognitive Behavioral Therapy (MI-CBT)
Study: 38679140
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care (EUC) involving AUD psychoeducation, advice to reduce drinking and seek treatment, and provision of community resources
Study: 38679416
Drug: Transperineal prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal prostate biopsy under local anaesthesia (LA) using 40 mL 1% lidocaine with 4 mL of 8.4% sodium bicarbonate.
Study: 38679697
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention promoting deprescribing of antidepressants
Study: 38679727
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs)
Study: 38680067
Drug: 14-day tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day tailored PCR-guided triple therapy (esomeprazole 40 mg, amoxicillin 1000 mg b.d., clarithromycin 500 mg or levofloxacin 500 mg b.d.)
Study: 38680067
Drug: 14-day non-Bismuth
Normalized name: bismuth subcitrate 14 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day non-Bismuth concomitant quadruple therapy (esomeprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg b.d.)
Study: 38680067
Drug: 14-day tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day tailored PCR-guided triple therapy
Study: 38680067
Drug: 14-day non-Bismuth
Normalized name: bismuth subcitrate 14 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day non-Bismuth concomitant quadruple therapy
Study: 38680067
Drug: Economic analysis
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Economic analysis of tailored PCR-guided triple therapy
Study: 38681788
Drug: High-flow oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow oxygen treatment (HFOT) through tracheostomy
Study: 38682205
Drug: Low-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yogurt enriched with Platelet-Activating Factor receptor (PAF-R) antagonists (150 g daily)
Study: 38683027
Drug: Crushed 200-mg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed 200-mg cenobamate tablet administered orally
Study: 38683027
Drug: Crushed 200-mg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed 200-mg cenobamate tablet administered via nasogastric tube
Study: 38683027
Drug: Intact 200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact 200-mg cenobamate tablet
Study: 38683596
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg once daily for 5 years
Study: 38683596
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 5 years
Study: 38683966
Drug: HA-1 TCR-T
Normalized name: NY-ESO-1 TCR T
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1 TCR-T therapy after lymphodepleting chemotherapy
Study: 38684039
Drug: Unesbulin 300
Normalized name: Unesbulin
DrugBank: Unesbulin (DB18080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unesbulin 300 mg administered orally twice per week plus DTIC 1,000 mg/m
Study: 38684046
Drug: Dutasteride 1
Normalized name: dutasteride 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 1 mg daily for 12 weeks
Study: 38684080
Drug: Patient partnership
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient partnership tools including a 1-page visit preparation guide and a library of short educational videos on medication safety.
Study: 38684243
Drug: Norepinephrine (dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (dilution to 0.016 mg/mL) using an electric syringe pump at a rate of 0.48 mg/h (30 mL/h) from the start of anaesthesia, titrated to achieve haemodynamic target.
Study: 38684243
Drug: Ephedrine, manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine, manual titration with a maximal dose of 30 mg, followed by perfusion with norepinephrine.
Study: 38684260
Drug: Maternal nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nightly positional therapy (PT)
Study: 38684260
Drug: Sham positional
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham positional therapy (sham-PT)
Study: 38684265
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (oral Vitamin D3 50,000 IU/week for 4 weeks, then 50,000 IU once every 2 weeks for 52 weeks)
Study: 38684276
Drug: Independently taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independently taking lethal medication attended by a confidant (ILMC)
Study: 38684631
Drug: Lovo-cel gene
Normalized name: Lovo-cel
DrugBank: Lovotibeglogene autotemcel (DB18680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovo-cel gene therapy
Study: 38684670
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment regimen for high-risk SMM patients
Study: 38684670
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment regimen for ultra-high risk (UHR) SMM patients
Study: 38685017
Drug: Outpatient Parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient Parenteral Antimicrobial Therapy (OPAT)
Study: 38685109
Drug: MMS for
Normalized name: Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMS for 180 days with one 180-count tablet bottle (MMS-180)
Study: 38685109
Drug: MMS for
Normalized name: Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMS for 180 days with two distributions of 90-count tablet bottles (MMS-90)
Study: 38685119
Drug: Women receiving
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women receiving chemotherapy
Study: 38685119
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who previously delayed breast cancer treatment more than 3 months
Study: 38685376
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of life-sustaining therapies (WLST)
Study: 38685481
Drug: 2-g out-of-hospital
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-g out-of-hospital TXA bolus
Study: 38685481
Drug: 1-g out-of-hospital
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion
Study: 38685481
Drug: Out-of-hospital saline
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-of-hospital saline bolus/in-hospital saline infusion (placebo)
Study: 38685704
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures retained by four titanium-zirconium mini implants
Study: 38685927
Drug: iTalkBetter (self-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTalkBetter (self-led app utilizing confrontation naming therapy)
Study: 38685972
Drug: inetetamab and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: inetetamab and pyrotinib (240 mg, 320 mg)
Study: 38686016
Drug: Dato-DXd monotherapy
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dato-DXd monotherapy
Study: 38686016
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of therapy (ICT; capecitabine, pembrolizumab, or capecitabine and pembrolizumab)
Study: 38686365
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 mg/kg) administered intravenously post-surgery
Study: 38686450
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 mcg bd daily for 4 weeks
Study: 38686879
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor inhibitor initiation
Study: 38687061
Drug: Probiotic intervention
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intervention (mixture of four probiotic strains with galacto-oligosaccharides) administered to mothers from the 36th week of pregnancy and to infants until 6 months of age.
Study: 38687136
Drug: E-cigarette inhalation
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-cigarette inhalation
Study: 38687339
Drug: Direct Cold
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Cold Atmospheric Plasma treatment, applied once or twice a week
Study: 38687481
Drug: 0.4-mg aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4-mg aflibercept injection
Study: 38687693
Drug: Educational training
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational training by a multidisciplinary team at hospital discharge and follow-up phone recall for therapy adherence.
Study: 38687741
Drug: Schroth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schroth treatment (Standard care + Schroth treatment)
Study: 38688118
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine (0.5 mg/kg, adjusted according to individual responses)
Study: 38688665
Drug: Low-dose metformin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metformin (500 mg two times per day)
Study: 38688665
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (1000 mg two times per day)
Study: 38688675
Drug: Dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg once daily as an add-on to ongoing SSRI treatment for 8 weeks
Study: 38688675
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily as an add-on to ongoing SSRI treatment for 8 weeks
Study: 38688675
Drug: Dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 30 mg once daily
Study: 38688998
Drug: Intranasal parent's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal parent's own milk (IPOM), given ideally twice daily until 28 days of age.
Study: 38689167
Drug: Self-assessment questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-assessment questionnaires about CRF, sleep disturbances, and emotional symptoms; accelerometer for physical activity and sleep quality; cognitive, neuromuscular, and exercise metabolism evaluations.
Study: 38689256
Drug: Concentrated exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated exposure treatment (cET) delivered during four consecutive days
Study: 38689269
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ddPCR with multiparameter flow cytometry (MFC)
Study: 38689304
Drug: Targeted BEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted BEP supplementation based on baseline nutritional status and monthly gestational weight gain monitoring (Arm 3)
Study: 38689324
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy treatments (up to five massages within a 4-month period)
Study: 38689324
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy treatments
Study: 38689402
Drug: Subdissociative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdissociative ketamine infusion (KI)
Study: 38690606
Drug: AZD9567 72
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9567 72 mg daily
Study: 38690606
Drug: AZD9567 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9567 40 mg daily
Study: 38690606
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg daily
Study: 38690733
Drug: Balance disruption
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance disruption between IFN-stimulated genes and IFN inhibitors.
Study: 38691209
Drug: Leucocyte-platelet-rich fibrin
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-platelet-rich fibrin (L-PRF) with coronally advanced flap (CAF)
Study: 38691316
Drug: Palopegteriparatide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palopegteriparatide treatment
Study: 38691387
Drug: Xanomeline-trospium chloride
Normalized name: trospium
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg)
Study: 38691622
Drug: Hematopoietic stem
Normalized name: Umbilical Cord Blood Hematopoietic Stem Cells
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic stem progenitor cell-gene therapy (HSPC-GT)
Study: 38691823
Drug: Whole-pelvic radiation
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvic radiation therapy (WPRT)
Study: 38692113
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) group therapy (n=49)
Study: 38692292
Drug: Recombinant ADAMTS13
Normalized name: ADAMTS13, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant ADAMTS13 (40 IU per kilogram of body weight, administered intravenously)
Study: 38692292
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (plasma-derived products)
Study: 38692428
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (MBI) tailored for adolescents with T1D; specific dosage and duration not mentioned.
Study: 38692712
Drug: Clinical pharmacologist-led
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacologist-led intervention including a detailed discharge medication management plan, a circle of care handover and early postdischarge virtual check-up visits to 1 month with 3-month follow-up.
Study: 38692727
Drug: adalimumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab (160 mg)
Study: 38693271
Drug: Intraoral cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral cold water spray
Study: 38693271
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cold water spray)
Study: 38693511
Drug: Ambroxol 1800
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 1800 mg/day
Study: 38693583
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (25 mg/kg), moxifloxacin (400 mg), pyrazinamide, isoniazid, aspirin (150 mg), and steroids for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Study: 38693583
Drug: Rifampicin, isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin, isoniazid, pyrazinamide (without aspirin) for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Study: 38693583
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to the National TB Elimination Program guidelines
Study: 38694503
Drug: XAV-19 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: XAV-19 (150 mg)
Study: 38694999
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine infusions
Study: 38695107
Drug: Drug-level feedback
Normalized name: MENTHOL, UNSPECIFIED FORM 100 mg in 1 g TOPICAL GEL [Evel Knievels Natural Choice Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-level feedback from urine testing
Study: 38695107
Drug: White coat
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White coat dosing behavior
Study: 38695310
Drug: SARS-CoV-2 RBD-based
Normalized name: RBD SARS-CoV-2 HBsAg VLP vaccine
DrugBank: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine (DB16431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 RBD-based VLP vaccine (LYB001) at doses of 30 or 60 µg
Study: 38695310
Drug: SARS-CoV-2 RBD-based
Normalized name: RBD SARS-CoV-2 HBsAg VLP vaccine
DrugBank: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine (DB16431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 RBD-based protein subunit vaccine (ZF2001, control group)
Study: 38695479
Drug: Lenvatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib + pembrolizumab + chemotherapy
Study: 38695527
Drug: Mavacamten dose-titration
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mavacamten dose-titration regimen guided by echocardiographic measures
Study: 38695604
Drug: SQZ-PBMC-HPV (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQZ-PBMC-HPV (administered as monotherapy every 3 weeks)
Study: 38696122
Drug: Osilodrostat (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osilodrostat (starting dose: 2 mg bid; maximum: 30 mg bid)
Study: 38696203
Drug: Combined Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Nicotine Replacement Therapy (CNRT)
Study: 38696203
Drug: Combined Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Nicotine Replacement Therapy (CNRT) and Varenicline
Study: 38696221
Drug: Intranasal (R,S)-Ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (R,S)-Ketamine
Study: 38696657
Drug: Inspiratory training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory training, details on dosage and duration not available
Study: 38696672
Drug: Ultra-Rapid Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultra-Rapid Lispro Insulin with Control-IQ Technology
Study: 38697155
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5·4 mg/kg intravenously once every 21 days)
Study: 38697155
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice (capecitabine, lapatinib, or trastuzumab)
Study: 38697156
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg) plus gemcitabine and cisplatin
Study: 38697182
Drug: AHCL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHCL therapy (MiniMed 780G)
Study: 38697184
Drug: Setmelanotide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setmelanotide (3.0 mg, subcutaneously once a day for 16 weeks)
Study: 38697216
Drug: Uniform Multidrug
Normalized name: Eugenia uniflora whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniform Multidrug Therapy (U-MDT) for 6 months
Study: 38697216
Drug: Regular Multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Multidrug Therapy (R-MDT) for 12 months
Study: 38697618
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg by mouth twice daily and capecitabine 1000 mg/m2 by mouth twice daily
Study: 38697677
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of once-weekly online Singing for Lung Health (SLH) sessions
Study: 38697766
Drug: Hospital at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital at home treatment
Study: 38698396
Drug: 6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml iPAAG injection
Study: 38698433
Drug: Active spinal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active spinal manual therapy
Study: 38698433
Drug: Placebo-control spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control spinal manual therapy
Study: 38698442
Drug: Supplemental enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition to achieve a high amount of enteral protein (2-2.4 g/kg/day)
Study: 38698442
Drug: No supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplemental enteral protein to achieve a moderate amount of enteral protein (0.8-1.2 g/kg/day)
Study: 38698442
Drug: Supplemental enteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental enteral protein (1.2 g/kg/day)
Study: 38698639
Drug: DopaFuse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DopaFuse therapy (continuous delivery of levodopa/carbidopa)
Study: 38698639
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral levodopa/carbidopa administration